Megan Sanders, Chief Executive Officer at Thoracic Oncology Group of Australasia, shared on LinkedIn:
“At TOGA’s post-ESMO International Conference Highlights, Dr. Tim Clay presented results from 3 phase III trials demonstrating how new treatments are expanding options for people with advanced non-small cell lung cancer.
OptiTROP-Lung06
In previously untreated, PD-L1-negative NSCLC, combining the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) with pembrolizumab increased median progression-free survival from 5.7 to 15.0 months compared with chemotherapy and pembrolizumab. Overall survival results are still maturing.
OptiTROP-Lung04
The same antibody-drug conjugate also improved survival in EGFR-mutated NSCLC following progression on EGFR-targeted therapy. Median overall survival increased from 17.4 to 25.9 months compared with chemotherapy.
These results demonstrate the growing potential of antibody-drug conjugates as alternatives to conventional chemotherapy.
SAFFRON
For patients with EGFR-mutated NSCLC who developed MET-driven resistance to osimertinib, combining osimertinib with the MET inhibitor savolitinib improved median overall survival from 12.9 to 17.8 months compared with chemotherapy.
In EGFR+NSCLC, the treatment landscape is expanding, but an important priority for future research is understanding resistance mechanisms and ensuring effective treatment options remain available as cancers continue to evolve.”
You can also read: What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment.
